（来源：淘金ETF） 1. 海泰新光（688677） 2. 华强科技（688151） 注册于湖北宜昌，主营业务聚焦特种防护装备、医药包装及医疗器械三大领域，医疗器械板块主打医用 防护用品、医用高分子材料等产品，涵盖医用防护服、口罩、注射器等品类。公司拥有完善的防护医疗 器械生产体系，在公共卫生应急物资保障领域具备核心优势。在脑机接口的医疗场景中，其研发的医用 防护装备可应用于脑机接口植入手术的无菌操作环境，而医用高分子材料也可适配脑机接口设备的生物 相容性部件研发。凭借军工级的生产质控标准，公司在医疗器械细分领域的产品竞争力持续提升。 3. 振德医疗（603301） 总部位于浙江绍兴，是国内医用敷料行业的龙头企业，主营医用敷料、康复护理、手术感控等医疗器械 产品，产品涵盖创口贴、纱布、手术衣、造口袋等全品类医用耗材。公司构建了"医用敷料+感控防护 +康复护理"的产品矩阵，销售网络覆盖全球130多个国家和地区。在脑机接口的临床应用环节，其手术 感控产品可满足脑机接口植入手术的无菌操作要求，康复护理类产品则能适配术后患者的康复管理需 求。2026年随着脑机接口医疗应用落地加速，公司的手术感控耗材业务有望迎来增量市 ...

数据显示，国泰基金旗下1只基金位居奥泰生物十大流通股东。国泰聚信价值优势灵活配置混合A （000362）三季度新进十大流通股东，持有股数71.33万股，占流通股的比例为0.9%。根据测算，今日 浮亏损失约47.79万元。 截至发稿，程洲累计任职时间17年276天，现任基金资产总规模0元，任职期间最佳基金回报365.56%， 任职期间最差基金回报-37%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 12月30日，奥泰生物跌1.05%，截至发稿，报63.24元/股，成交421.86万元，换手率0.08%，总市值50.14 亿元。 国泰聚信价值优势灵活配置混合A（000362）成立日期2013年12月17日，最新规模15.43亿。今年以来收 益33.61%，同类排名2626/8087；近一年收益30.99%，同类排名2747/8085；成立以来收益365.93%。 国泰聚信价值优势灵活配置混合A（000362）基金经理为程洲。 资料显示，杭州奥泰生物技术股份有限公司位于浙 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688606 证券简称：奥泰生物 公告编号：2025-056 杭州奥泰生物技术股份有限公司 关于 2024 年限制性股票激励计划首次授予第一个归 属期归属结果的公告 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，杭州奥泰生物技术股份有限公司（以下 简称"公司"）于 2025 年 12 月 11 日收到中国证券登记结算有限责任公司上海 分公司出具的《过户登记确认书》，完成了公司 2024 年限制性股票激励计划（以 下简称"本次激励计划"）首次授予第一个归属期归属的股份登记工作。现将有 关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2024 年 9 月 2 日，公司召开第三届董事会第七次会议，审议并通过 《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2024 年限制性股票激励计划实施考核管理办法>的议案》《关于提请公司股 东大会授权董事 ...

Core Viewpoint - The article discusses the recent sample adjustment of the CSI Dividend Index, highlighting the reasons for the removal and addition of stocks, and the overall impact on the index's quality and dividend yield [3][9]. Sample Adjustment Information and Logic Analysis - The CSI Dividend Index underwent a sample adjustment involving 20 stocks, accounting for 20% of the total sample size [5]. - Stocks were removed primarily due to low dividend yields, liquidity issues, or excessively high payout ratios [6]. - Notably, many stocks were removed because their dividend yields fell below acceptable levels, often due to declining performance [6]. Stocks Removed from the Index - Stocks such as Aotai Biological, Baosteel, and Dashiang were removed due to low dividend yields, with Baosteel's yield at 3.68% and Aotai's at 5.62% [5]. - Other reasons for removal included liquidity issues for companies like Dashiang and Fuanna, and high payout ratios for companies like Huafa and Xiangzhong Energy [5]. Stocks Added to the Index - New additions included stocks like Anhui Construction and Baoxini, which had higher dividend yields, with Anhui's yield at 5.46% [7]. - The adjustment included a diverse range of industries, enhancing the index's overall sector representation [8]. Comparison of Basic Data Before and After Adjustment - The overall financial performance of stocks added to the index was superior to those removed, with net profit growth of -2.94% for new additions compared to -23.52% for those removed [11]. - The return on equity (ROE) for new additions was 12.93%, indicating stronger financial health [11]. Valuation and Performance Comparison - The average price-to-earnings (PE) ratio for stocks added to the index was significantly lower than those removed, suggesting improved valuation metrics [13]. - The average dividend yield for new additions increased by 36 basis points compared to those removed, reflecting a more attractive income potential [13]. Conclusion - The adjustments to the CSI Dividend Index are expected to enhance its dividend yield and overall quality, while also reducing the PE ratio, thereby maintaining its long-term investment value [15].

Core Points - The Shanghai Composite Index closed at 3875.26 points, above the annual line, with a change of 0.29% [1] - The total trading volume of A-shares reached 1,723.17 billion yuan [1] - A total of 87 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Qingniao Firefighting (002960) saw a price increase of 10.03% with a deviation rate of 9.78% [1] - Tianyi New Materials (688033) increased by 20.04%, with a deviation rate of 7.79% [1] - Liande Equipment (300545) rose by 20.01%, showing a deviation rate of 6.16% [1] Trading Activity - The trading turnover rate for Qingniao Firefighting was 2.39% [1] - Tianyi New Materials had a turnover rate of 12.35% [1] - Liande Equipment recorded a turnover rate of 19.65% [1] Annual Line Breakthroughs - The stocks with the largest deviation rates from the annual line include: - Qingniao Firefighting: 9.78% [1] - Tianyi New Materials: 7.79% [1] - Liande Equipment: 6.16% [1] - Other stocks that just crossed the annual line include: - China Merchants Port, Aotai Biological, and Rongtai Health, with smaller deviation rates [1]

Core Viewpoint - The company, Aotai Biology, reported that as of October 31, 2025, the total number of shareholders is 5,665 [1] Summary by Categories - **Company Information** - Aotai Biology has a total of 5,665 shareholders as of the specified date [1]

Meeting Overview - The second extraordinary general meeting of shareholders was held on November 25, 2025, at the company's conference room in Hangzhou, Zhejiang Province [2] - The total share capital as of the meeting's registration date was 79,280,855 shares, with 973,631 shares in the company's repurchase account not entitled to vote [2] Voting and Attendance - The meeting was convened by the board of directors and chaired by Mr. Gao Fei, utilizing a combination of on-site and online voting methods [4] - All five current directors and three current supervisors attended the meeting, along with the board secretary [4] Resolutions Passed - The following resolutions were approved: - Cancellation of the supervisory board and amendments to the Articles of Association [5] - Revisions to various internal management systems, including: - Shareholders' meeting rules - Board meeting rules - Independent director work system - Related party transaction management system - Prevention of related party fund occupation management system - External guarantee management system - External investment management system - Cumulative voting implementation details - Fundraising management measures [6][7] Legal Compliance - The meeting was witnessed by Shanghai Lifeng Law Firm, confirming that the convening, holding, and voting procedures complied with relevant laws and regulations [8]

Core Points - The company announced the election of Mr. Gao Yuecan as the employee representative director of the third board of directors during the second meeting of the third employee representative assembly held on November 25, 2025 [2]

证券代码：688606 证券简称：奥泰生物 公告编号：2025-054 杭州奥泰生物技术股份有限公司 关于完成董事增选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、选举独立董事的情况 杭州奥泰生物技术股份有限公司（以下简称"公司"）于2025年10月30日召开了 第三届董事会第十七次会议，审议通过了《关于增选第三届董事会独立董事的议案》， 公司董事会同意提名陈善基先生为公司第三届董事会独立董事，任期自股东大会审议 通过之日起至第三届董事会任期届满之日止。具体内容详见公司于2025年10月31日在 上海证券交易所网站（www.sse.com.cn）披露的《关于增选第三届董事会独立董事的 公告》（公告编号：2025-051）。 2025年11月25日，公司召开了2025年第二次临时股东大会，增选陈善基先生为公 司第三届董事会独立董事，任期自本次股东大会审议通过之日起至第三届董事会任期 届满之日止。 二、选举职工董事的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）和修订后的《杭州 奥泰生物技术股份有限 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-055 杭州奥泰生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （二） 股东大会召开的地点：浙江省杭州市钱塘区下沙街道乔新路 383 号公司 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 66 | | --- | --- | | 普通股股东人数 | 66 | | 2、出席会议的股东所持有的表决权数量 | 52,995,653 | | 普通股股东所持有表决权数量 | 52,995,653 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 67.6766 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 67.6766 | 注：截至本次股东大会股权登记日的总股本为 79,280,855 股；其中公司回购专用 ...